Sequential Treatment of Extra-Corporeal Shock Wave Combined With aUtologous Bone marRow Mesenchymal Stem Cells on Patients With ischEmic Heart Disease : the S-CURE Study

Inclusion Criteria: 1. Males and non-pregnant, non-lactating females; 2. Chronic ischemic heart failure, previous anterior myocardial infarction \> 3months; 3. Viable myocardium is detected by D-SPECT; 4. LVEF \< 50% measured by echocardiography or NYHA II-IV; 5. No planed reasonable revascularization procedures; 6. At least 30 days standard medical therapy for heart failure before screening; 7. Worsening heart failure within 6 months or have a NT-proBNP ≥1000 pg/mL or BNP ≥200 pg/mL within 30 days of screening (including screening); or have a 6-minute walk test (6MWT) distance of ≤425 meters at screening; 8. Written informed consent. Exclusion Criteria: 1. Ventricular thrombus; 2. Myocardial infarction, TIA or stroke \< 3 months; 3. CRT/CRT-D implantation, heart transplantation, cardiomyoplasty, left ventricular reduction surgery, heart failure-related device interventions, or cardiac shunt implantation; 4. Active infection or fever; 5. Chronic inflammatory disease; 6. HIV infection or active hepatitis; 7. Hemoglobin A1c (HbA1c) ≥ 9% at screening; 8. Body mass index (BMI) ≥ 40 kg/m2 at screening; 9. Chronic kidney disease (CKD) requiring dialysis (Stage 5) or estimated creatinine clearance \< 30 mL/min/1.73㎡ at screening; 10. Allergies to any equine, porcine, or bovine products; 11. Abnormal laboratory values at screening：Platelets \< 50,000 μL;Hemoglobin \< 9.0 g/dL; Aspartate aminotransferase/alanine aminotransferase (AST/ALT) \> 3 times the upper limit of normal (ULN); 12. Pregnancy; 13. Mental retardation; 14. Participation in other clinical study \< 1 month.